CA9 and renal cell carcinoma: DNA vaccines encoding carbonic anhydrase IX (CAIX) and survivin—two antigens overexpressed in RCC but minimally expressed in normal tissue—have demonstrated potent antitumor efficacy in preclinical studies [34].